Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0070 • ACR Convergence 2021
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Ecem Sevim², Guilherme Ramires de Jesus³, Ricard Cervera⁴, Lanlan Ji⁵, Vittorio Pengo⁶, Amaia Ugarte⁷, Danieli Andrade⁸, Laura Andreoli⁹, Tatsuya Atsumi¹⁰, Paul R Fortin¹¹, Maria Gerosa¹², Yu Zuo¹³, Michelle Petri¹⁴, Savino Sciascia¹⁵, Maria Tektonidou¹⁶, Maria Angeles Aguirre¹⁷, D. Ware Branch¹⁸, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Montefiore Medical Center - Wakefield Campus, Bronx, NY, ³Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Peking University First Hospital, Beijing, China (People's Republic), ⁶Padova University Hospital, Padova, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹University of Brescia, Brescia, Italy, ¹⁰Hokkaido University, Sapporo, Japan, ¹¹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹²University of Milan, Milan, Italy, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Turin, Turin, Italy, ¹⁶FORZAFORTE HELLAS LTD, Athens, Greece, ¹⁷IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹⁸University of Utah, Salt Lake City, UT
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
Abstract Number: 0950 • ACR Convergence 2021
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa
Ecem Sevim¹, Salma Siddique², Madhavi Latha Chalasani³, Susan Chyou⁴, William Shipman³, Orla O`Shea⁵, Oral Alpan⁶, Stephane Zuily⁷, Joanna Harp⁸, Theresa Lu³ and Doruk Erkan³, ¹Montefiore Medical Center - Wakefield Campus, Bronx, NY, ²Nemours/A.I.duPont Hospital for Children, Wilmington, DE, ³Hospital for Special Surgery, New York, NY, ⁴Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ⁵Analytical Microscopy Core Laboratory, Hospital for Special Surgery, New York, NY, ⁶O&O Alpan Medical Center, Vienna, VA, ⁷Nancy Academic Hospital, Vandoeuvre-ls-Nancy, France, ⁸Dermatology, Weill Cornell Medicine, New York, NY
Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microvascular disease. The mTOR pathway plays a role in the endothelial proliferation…
Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Gustavo Balbi¹, Yasaman Ahmadzadeh², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul R Fortin⁹, Chary lopez-pedrera¹⁰, Lanlan Ji¹¹, Tatsuya Atsumi¹², Hannah Cohen¹³, Guilherme Ramires de Jesus¹⁴, D. Ware Branch¹⁵, Cecilia Nalli¹⁶, Nina Kello¹⁷, Michelle Petri¹⁸, Esther Rodriguez-Almaraz¹⁹, Giuseppe Barilaro²⁰, Jason Knight²¹, Bahar Artim-Esen²², Rohan Willis²³, Maria Laura Bertolaccini²⁴, Robert Roubey²⁵, Doruk Erkan², Danieli De Andrade¹ and on Behalf of APS ACTION², ¹University of São Paulo, São Paulo, Brazil, ²Hospital for Special Surgery, New York, NY, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵University of Turin, Turin, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸University of Milan, Milan, Italy, ⁹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Hokkaido University, Sapporo, Japan, ¹³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁷Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Clínic Barcelona - Hospital Universitari, Barcelona, Spain, ²¹University of Michigan, Ann Arbor, MI, ²²Istanbul University School of Medicine, İstanbul, Turkey, ²³University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…
Abstract Number: 0951 • ACR Convergence 2021
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Elena Gkrouzman¹, Danieli Andrade², Maria Tektonidou³, Vittorio Pengo⁴, Amaia Ugarte⁵, H. Michael Belmont⁶, Cecilia Chighizola⁷, Paul R Fortin⁸, Tatsuya Atsumi⁹, Maria Efthymiou,¹⁰, Guilherme Ramires de Jesus¹¹, D. Ware Branch¹², Laura Andreoli¹³, Michelle Petri¹⁴, Esther Rodriguez-Almaraz¹⁵, Ricard Cervera¹⁶, Jason Knight¹⁷, Emilio Gonzalez¹⁸, Elisa Bison¹⁹, Ian Mackie²⁰, Hannah Cohen²¹, Maria Laura Bertolaccini²², Doruk Erkan²³, Robert Roubey²⁴ and on behalf of APS ACTION²³, ¹University of Massachusetts, Shrewsbury, MA, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵Hospital Universitario Cruces, Barakaldo, Spain, ⁶NYU School of Medicine, New York, NY, ⁷University of Milan, Milan, Italy, ⁸CHU de Quebec - Universite Laval, Québec City, QC, Canada, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³University of Brescia, Brescia, Italy, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Hospital Clinic Barcelona, Barcelona, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas Medical Branch (utmb Health), Galveston, TX, ¹⁹University of Padova, Padova, Italy, ²⁰University College London, London, United Kingdom, ²¹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ²²King's College London, London, United Kingdom, ²³Hospital for Special Surgery, New York, NY, ²⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: Several antiphospholipid antibody (aPL) profiles are associated with a higher risk for the clinical manifestations of the antiphospholipid syndrome (APS). These include “triple positivity”…
Abstract Number: 0072 • ACR Convergence 2021
Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Rebecca Karp- Leaf², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Amaia Ugarte⁷, H. Michael Belmont⁸, Maria Gerosa⁹, Paul R Fortin¹⁰, Chary lopez-pedrera¹¹, Lanlan Ji¹², Tatsuya Atsumi¹³, Hannah Cohen¹⁴, Guilherme Ramires de Jesus¹⁵, D. Ware Branch¹⁶, Cecilia Nalli¹⁷, Nina Kello¹⁸, Michelle Petri¹⁹, Esther Rodriguez-Almaraz²⁰, Ricard Cervera²¹, Jason Knight²², Bahar Artim-Esen²³, Rohan Willis²⁴, Maria Laura Bertolaccini²⁵, Robert Roubey²⁶, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Boston, MA, ³Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴FORZAFORTE HELLAS LTD, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸NYU School of Medicine, New York, NY, ⁹University of Milan, Milan, Italy, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹¹IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Hokkaido University, Sapporo, Japan, ¹⁴Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶University of Utah, Salt Lake City, UT, ¹⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁸Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clinic Barcelona, Barcelona, Spain, ²²University of Michigan, Ann Arbor, MI, ²³Istanbul University School of Medicine, İstanbul, Turkey, ²⁴University of Texas Medical Branch, Galveston, TX, ²⁵King's College London, London, United Kingdom, ²⁶University of North Carolina, Chapel Hill, NC
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
Abstract Number: 0962 • ACR Convergence 2021
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Arielle Mendel¹, Marvin Fritzler², Yvan St.Pierre¹, Joyce Rauch³, Sasha Bernatsky³ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although several studies indicate that patients with COVID-19 produce antiphospholipid antibodies (aPL), it is unclear which aPL subtype predominates and whether aPL correlates with…
Abstract Number: 0073 • ACR Convergence 2021
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
Cecilia Chighizola¹, Francesca Pregnolato², Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Paul R Fortin⁸, Tatsuya Atsumi⁹, Maria Efthymiou,¹⁰, Guilherme Ramires de Jesus¹¹, D. Ware Branch¹², Cecilia Nalli¹³, Michelle Petri¹⁴, Esther Rodriguez-Almaraz¹⁵, Ricard Cervera¹⁶, Yu Zuo¹⁷, Rohan Willis¹⁸, Elisa Bison¹⁹, Ian Mackie²⁰, Hannah Cohen²¹, Robert Roubey²², Doruk Erkan²³ and Maria Laura Bertolaccini²⁴, ¹University of Milan, Milan, Italy, ²Università degli Studi di Milano, Milan, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸CHU de Quebec - Universite Laval, Québec City, QC, Canada, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Hospital Clinic Barcelona, Barcelona, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas Medical Branch, Galveston, TX, ¹⁹University of Padova, Padova, Italy, ²⁰University College London, London, United Kingdom, ²¹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ²²UNC, Chapel Hill, NC, ²³Hospital for Special Surgery, New York, NY, ²⁴King's College London, London, United Kingdom
Background/Purpose: Data on fluctuation of antibodies against domain 1 (anti-D1) of β2-glycoprotein I (β2GPI) are scarce. Patients with antiphospholipid syndrome (APS) and all three criteria…
Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Goncalo Durao-Carvalho¹, Raquel Fernandez², Bethan Goulden³, Filipa Farinha⁴ and David Isenberg⁵, ¹Servico de Medicina Interna, Centro Hospitalar do Oeste – Unidade de Caldas da Rainha, Caldas da Rainha, Portugal, Caldas da Rainha, Portugal, ²Servicio de Medicina Interna, Hospital Universitario de Ourense, Ourense, Spain, ³Department of Rheumatology, University College London Hospitals, London, United Kingdom, ⁴Department of Rheumatology, University College London Hospitals and Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
Abstract Number: 0938 • ACR Convergence 2020
Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Cecilia Nalli¹, Daniele Lini², Laura Andreoli², Francesca Crisafulli², Micaela Fredi², Maria Grazia Lazzaroni², Victoria Bitsadze³, Antonia Calligaro⁴, Valentina Canti⁵, Roberto Caporali⁶, Francesco Carubbi⁷, Cecilia Chighizola⁸, Paola Conigliaro⁹, Caterina De Carolis¹⁰, Teresa Del Ross⁴, Maria Favaro⁴, Maria Gerosa¹¹, Annamaria Iuliano¹², Jamilya Khizroeva³, Alexander Makatsariya³, Pierlugi Meroni¹³, Marta Mosca¹⁴, Melissa Padovan¹⁵, Roberto Perricone⁹, Patrizia Rovere-Querini¹⁶, Gian Domenico Sebastiani¹², Chiara Tani¹⁴, Marta Tonello⁴, Dina Zucchi¹⁴, Franco Franceschini¹⁷ and Angela Tincani², ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Department of Obstetrics and Gynecology of I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁴Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy, ⁵Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁸Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Experimental Laboratory of Immunorheumatological Researches, Istituto Auxologico Italiano, Milan, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹⁰Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹¹Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milan, Italy, ¹²Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹³Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵UO e Sezione di Reumatologia, Dipartimento di Scienze Mediche, Universita' degli Studi di Ferrara, Ferrara, Italy, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Milan, Italy, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: The role of complement in the aPL related pathology has been widely studied in animal models. aPL can induce fetal loss in experimental animals but…
Abstract Number: 1261 • ACR Convergence 2020
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
Abstract Number: 0429 • ACR Convergence 2020
Prothrombotic Antiphospholipid Antibodies in COVID-19
Yu Zuo¹, Shanea Estes², Alex Ghandi³, Srilakshmi Yalavarthi³, Ramadan Ali³, Shi Hui³, Gautam Sule³, Kelsey Gockman³, Jacqueline Madison³, Melanie Zuo³, Wrenn Woodard³, Sean Lezak³, Njira Lugogo³, Yogendra Kanthi⁴ and Jason Knight¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombosis of arteries and veins. At the same time, COVID-19 lung histopathology has…
Abstract Number: 1262 • ACR Convergence 2020
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
Abstract Number: 0519 • ACR Convergence 2020
Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid
Rohan Willis¹, E Nigel Harris², Vijaya Murthy³, Zurina Romay-Penabad¹, Alvaro Schleh⁴, Monica Smikle², Karel De Ceulaer², Anne Tebo⁵, Troy Jaskowski⁶, Marta Guerra⁷, David Ware Branch⁸, Jane Salmon⁷, Michelle Petri⁹ and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³University of Texas Medical Branch, League City, TX, ⁴Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁵Department of Pathology, University of Utah, Salt Lake City, ⁶ARUP Laboratories, Salt Lake City, UT, ⁷Hospital for Special Surgery, New York, NY, ⁸University of Utah, Salt Lake City, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…
Abstract Number: 1447 • ACR Convergence 2020
Vitamin D Deficiency Enhances Antiphospholipid Antibody-Mediated Thrombosis in a Passive Immunization Mouse Model
Rohan Willis¹, Karen Roye-Green², Zurina Romay-Penabad¹, Elizabeth Papalardo¹, Alvaro Schleh³, Vijaya Murthy⁴, Monica Smikle² and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁴University of Texas Medical Branch, League City, TX
Background/Purpose: Abnormal vitamin D levels occur frequently in antiphospholipid (APS) patients and are correlated with thrombosis. It remains unclear however if vitamin D deficiency observed…
Abstract Number: 0520 • ACR Convergence 2020
Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward
Alexandre Le Joncour¹, Corinne Frere¹, Isabelle Martin-Toutain¹, Paul Gougis¹, Pascale Ghillani-Dalbin¹, Georgina Maalouf¹, Matheus Vieira¹, Anne-Genevieve Marcelin¹, Joe-Elie Salem¹, Yves Allenbach², David Saadoun³, Olivier Benveniste⁴ and Patrice Cacoub¹, ¹APHP, paris, France, ²Sorbonne Université, Paris, Ile-de-France, France, ³AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, PAris, France, ⁴Sorbonne Université, paris, France
Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].